1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Toxicology Drug Testing Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Toxicology Drug Testing Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancements
    5.2. Regulatory Scenario by Region/Globally
    5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Testing Type, 2017-2031
        6.3.1. In Vitro
        6.3.2. In Vivo
        6.3.3. In Silico
    6.4. Market Attractiveness Analysis, by Testing Type
7. Global Toxicology Drug Testing Market Analysis and Forecast, by Testing Method
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Testing Method, 2017-2031
        7.3.1. Mass Spectrometry Imaging
        7.3.2. Electron Microscopy
        7.3.3. Fluorescence Labeling
        7.3.4. Immunohistochemistry
        7.3.5. Others
    7.4. Market Attractiveness Analysis, by Testing Method
8. Global Toxicology Drug Testing Market Analysis and Forecast, by Application
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by Application, 2017-2031
        8.3.1. Drug Development
        8.3.2. Substance Abuse and Addiction
        8.3.3. Therapeutic Drug Monitoring
        8.3.4. Others
    8.4. Market Attractiveness Analysis, by Application
9. Global Toxicology Drug Testing Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings/Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Cosmetics Industry
        9.3.2. Healthcare Industry
            9.3.2.1. Hospital and Clinics
            9.3.2.2. Diagnostic Laboratories
            9.3.2.3. Pharmaceutical & Biotechnology Companies
            9.3.2.4. Others
        9.3.3. Food Industry
        9.3.4. Chemicals Industry
    9.4. Market Attractiveness Analysis, by End-user
10. Global Toxicology Drug Testing Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region, 2017-2031
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness By Country/Region
11. North America Toxicology Drug Testing Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Testing Type, 2017-2031
        11.2.1. In Vitro
        11.2.2. In Vivo
        11.2.3. In Silico
    11.3. Market Value Forecast, by Testing Method, 2017-2031
        11.3.1. Mass Spectrometry Imaging
        11.3.2. Electron Microscopy
        11.3.3. Fluorescence Labeling
        11.3.4. Immunohistochemistry
        11.3.5. Others
    11.4. Market Value Forecast, by Application, 2017-2031
        11.4.1. Drug Development
        11.4.2. Substance Abuse and Addiction
        11.4.3. Therapeutic Drug Monitoring
        11.4.4. Others
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Cosmetics Industry
        11.5.2. Healthcare Industry
            11.5.2.1. Hospital and Clinics
            11.5.2.2. Diagnostic Laboratories
            11.5.2.3. Pharmaceutical & Biotechnology Companies
            11.5.2.4. Others
        11.5.3. Food Industry
        11.5.4. Chemicals Industry
    11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Testing Type
        11.7.2. By Testing Method
        11.7.3. By Application
        11.7.4. By End-user
        11.7.5. By Country/Sub-region
12. Europe Toxicology Drug Testing Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Testing Type, 2017-2031
        12.2.1. In Vitro
        12.2.2. In Vivo
        12.2.3. In Silico
    12.3. Market Value Forecast, by Testing Method, 2017-2031
        12.3.1. Mass Spectrometry Imaging
        12.3.2. Electron Microscopy
        12.3.3. Fluorescence Labeling
        12.3.4. Immunohistochemistry
        12.3.5. Others
    12.4. Market Value Forecast, by Application, 2017-2031
        12.4.1. Drug Development
        12.4.2. Substance Abuse and Addiction
        12.4.3. Therapeutic Drug Monitoring
        12.4.4. Others
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Cosmetics Industry
        12.5.2. Healthcare Industry
            12.5.2.1. Hospital and Clinics
            12.5.2.2. Diagnostic Laboratories
            12.5.2.3. Pharmaceutical & Biotechnology Companies
            12.5.2.4. Others
        12.5.3. Food Industry
        12.5.4. Chemicals Industry
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Testing Type
        12.7.2. By Testing Method
        12.7.3. By Application
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Toxicology Drug Testing Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Testing Type, 2017-2031
        13.2.1. In Vitro
        13.2.2. In Vivo
        13.2.3. In Silico
    13.3. Market Value Forecast, by Testing Method, 2017-2031
        13.3.1. Mass Spectrometry Imaging
        13.3.2. Electron Microscopy
        13.3.3. Fluorescence Labeling
        13.3.4. Immunohistochemistry
        13.3.5. Others
    13.4. Market Value Forecast, by Application, 2017-2031
        13.4.1. Drug Development
        13.4.2. Substance Abuse and Addiction
        13.4.3. Therapeutic Drug Monitoring
        13.4.4. Others
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Cosmetics Industry
        13.5.2. Healthcare Industry
            13.5.2.1. Hospital and Clinics
            13.5.2.2. Diagnostic Laboratories
            13.5.2.3. Pharmaceutical & Biotechnology Companies
            13.5.2.4. Others
        13.5.3. Food Industry
        13.5.4. Chemicals Industry
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Testing Type
        13.7.2. By Testing Method
        13.7.3. By Application
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Toxicology Drug Testing Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Testing Type, 2017-2031
        14.2.1. In Vitro
        14.2.2. In Vivo
        14.2.3. In Silico
    14.3. Market Value Forecast, by Testing Method, 2017-2031
        14.3.1. Mass Spectrometry Imaging
        14.3.2. Electron Microscopy
        14.3.3. Fluorescence Labeling
        14.3.4. Immunohistochemistry
        14.3.5. Others
    14.4. Market Value Forecast, by Application, 2017-2031
        14.4.1. Drug Development
        14.4.2. Substance Abuse and Addiction
        14.4.3. Therapeutic Drug Monitoring
        14.4.4. Others
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Cosmetics Industry
        14.5.2. Healthcare Industry
            14.5.2.1. Hospital and Clinics
            14.5.2.2. Diagnostic Laboratories
            14.5.2.3. Pharmaceutical & Biotechnology Companies
            14.5.2.4. Others
        14.5.3. Food Industry
        14.5.4. Chemicals Industry
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Testing Type
        14.7.2. By Testing Method
        14.7.3. By Application
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Toxicology Drug Testing Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Testing Type, 2017-2031
        15.2.1. In Vitro
        15.2.2. In Vivo
        15.2.3. In Silico
    15.3. Market Value Forecast, by Testing Method, 2017-2031
        15.3.1. Mass Spectrometry Imaging
        15.3.2. Electron Microscopy
        15.3.3. Fluorescence Labeling
        15.3.4. Immunohistochemistry
        15.3.5. Others
    15.4. Market Value Forecast, by End-user, 2017-2031
        15.4.1. Drug Development
        15.4.2. Substance Abuse and Addiction
        15.4.3. Therapeutic Drug Monitoring
        15.4.4. Others
    15.5. Market Value Forecast, by Application, 2017-2031
        15.5.1. Cosmetics Industry
        15.5.2. Healthcare Industry
            15.5.2.1. Hospital and Clinics
            15.5.2.2. Diagnostic Laboratories
            15.5.2.3. Pharmaceutical & Biotechnology Companies
            15.5.2.4. Others
        15.5.3. Food Industry
        15.5.4. Chemicals Industry
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Testing Type
        15.7.2. By Testing Method
        15.7.3. By Application
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. TDAL Labs
            16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.1.2. Product Portfolio
            16.3.1.3. Financial Overview
            16.3.1.4. SWOT Analysis
            16.3.1.5. Strategic Overview
        16.3.2. Thermo Fisher Scientific Inc.
            16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.2.2. Product Portfolio
            16.3.2.3. Financial Overview
            16.3.2.4. SWOT Analysis
            16.3.2.5. Strategic Overview
        16.3.3. Abbott
            16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.3.2. Product Portfolio
            16.3.3.3. Financial Overview
            16.3.3.4. SWOT Analysis
            16.3.3.5. Strategic Overview
        16.3.4. Icahn School of Medicine at Mount Sinai
            16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.4.2. Product Portfolio
            16.3.4.3. Financial Overview
            16.3.4.4. SWOT Analysis
            16.3.4.5. Strategic Overview
        16.3.5. Clinisys, Inc.
            16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.5.2. Product Portfolio
            16.3.5.3. Financial Overview
            16.3.5.4. SWOT Analysis
            16.3.5.5. Strategic Overview
        16.3.6. Laboratory Corporation of America Holdings
            16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.6.2. Product Portfolio
            16.3.6.3. Financial Overview
            16.3.6.4. SWOT Analysis
            16.3.6.5. Strategic Overview
        16.3.7. SLUCARE
            16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.7.2. Product Portfolio
            16.3.7.3. Financial Overview
            16.3.7.4. SWOT Analysis
            16.3.7.5. Strategic Overview
        16.3.8. Keystone Lab
            16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.8.2. Product Portfolio
            16.3.8.3. Financial Overview
            16.3.8.4. SWOT Analysis
            16.3.8.5. Strategic Overview
        16.3.9. Shimadzu Scientific Instruments
            16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.9.2. Product Portfolio
            16.3.9.3. Financial Overview
            16.3.9.4. SWOT Analysis
            16.3.9.5. Strategic Overview
        16.3.10. Ganesh Diagnostic & Imaging Centre Pvt. Ltd.
            16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.10.2. Product Portfolio
            16.3.10.3. Financial Overview
            16.3.10.4. SWOT Analysis
            16.3.10.5. Strategic Overview
        16.3.11. Other Players
            16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            16.3.11.2. Product Portfolio
            16.3.11.3. Financial Overview
            16.3.11.4. SWOT Analysis
            16.3.11.5. Strategic Overview
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer



 
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			 
					
							
			